BOTOX® (Allergan's botulinum toxin type A) Given Final Guidance from the National Institute for Health and Clinical Excellence (NICE) for the Prevention of Chronic Migraine in Patients Who Have Failed Previous Treatments
BOTOX® (Allergan's botulinum toxin type A) Given Final Guidance from the National Institute for Health and Clinical Excellence (NICE) for the Prevention of Chronic Migraine in Patients Who Have Failed Previous Treatments PR Newswire MARLOW, England, June 27, 2012 MARLOW, England, June 27, 2012 /PRNewswire/ -- Allergan announced today that the National Institute for Health and Clinical Excellence (NICE) has issued its Final Guidance giving the green light for ®BOTOX (botulinum toxin type A) to be used on the NHS as prophylaxis (prevention) against headache in adults with chronic migraine*, specifically in patients who have not responded to at least three prior preventative treatments and whose condition is appropriately managed for medication [1]overuse. This means that Primary Care Trusts (PCTs) in England and Wales now have 90 days to make funding and resources available to treat patients suffering from this debilitating condition with BOTOX®. Allergan's BOTOX® is the only botulinum toxin type A to have received authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for the [2]prevention of headache in chronic migraine. Wendy Thomas, Chief Executive of The Migraine Trust comments, "This decision is widely welcomed by the migraine community as these patients are frequently debilitated and are often poorly served by the NHS.